Sunitinib for refractory malignant pheochromocytoma: two case reports. - Wikidata - wikimedia - TriplyDB

Sunitinib for refractory malignant pheochromocytoma: two case reports.

Sunitinib for refractory malignant pheochromocytoma: two case reports.

http://www.wikidata.org/entity/Q33413239

about

The Roles of PI3K/AKT/mTOR and MAPK/ERK Signaling Pathways in Human Pheochromocytomas.Sunitinib in the therapy of malignant paragangliomas: report on the efficacy in a SDHB mutation carrier and review of the literature.

P2860

Q37470890-63ADBBD9-6951-489B-8AAF-AE71F22C14B2 Q51397534-D143E108-157F-436B-B37D-CB09C5EC4D6E

P2860

Sunitinib for refractory malignant pheochromocytoma: two case reports.

http://www.wikidata.org/entity/Q33413239

description

2014 nî lūn-bûn

@nan

2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Sunitinib for refractory malignant pheochromocytoma: two case reports.

@ast

Sunitinib for refractory malignant pheochromocytoma: two case reports.

@en

type

label

Sunitinib for refractory malignant pheochromocytoma: two case reports.

@ast

Sunitinib for refractory malignant pheochromocytoma: two case reports.

@en

prefLabel

Sunitinib for refractory malignant pheochromocytoma: two case reports.

@ast

Sunitinib for refractory malignant pheochromocytoma: two case reports.

@en

P1433

Q33413239-A3EDEFC7-B7F0-4703-AC74-F8501F176825

P1476

Q33413239-574CD0B6-5A7F-41C5-AD8C-33EDFF911D97

P2093

Q33413239-01C50F6A-F207-4423-B6FA-85BFA6E0AAF7

Q33413239-37DE1B8C-4E5D-4F53-8F45-569CC52D1702

Q33413239-4FA5466F-B057-444D-B0BD-3E332B98F57E

Q33413239-6A63CE98-7BAD-4946-A596-9E0C06ADE519

Q33413239-80988FFE-26E6-4004-9956-BF6FFF23973A

Q33413239-869B56B2-2C87-4B22-B3BD-14212C812072

Q33413239-B6531977-4DE6-4A15-B15E-A28746DB3ADD

Q33413239-D84C9978-3B18-4C43-8741-74C7B91F83F4

Q33413239-DCD87877-5FE4-4F56-A015-CB270F2EA21C

Q33413239-E221E39B-5B22-4501-940B-B9DA64C1FD57

P2860

Q33413239-298FDEC4-6966-4624-8111-DBABC6CF1E83

Q33413239-469ACE5F-7FFD-4378-88BD-3195457D5430

Q33413239-BF52B86C-9577-4A86-8C1C-60B2441D45B8

Q33413239-E0E841F9-4F88-4687-9CBE-F714DD083B55

Q33413239-E6ED88F2-2A5F-4AE4-81CD-A85DA605740C

Q33413239-F5FB3D11-F0B8-4E30-8D7A-677758938FF3

Q33413239-F90EC895-D155-4501-81FC-4920A9AFE835

P304

Q33413239-6D1525AE-3324-46E9-AC65-4CC51E7FD908

P31

Q33413239-8522B08F-C4A0-4C80-8F20-A7CCF02E4C3A

P356

Q33413239-0C0058F6-BA7E-4F66-833A-4322D4442ADC

P433

Q33413239-AAC05987-D3FD-4954-B5DF-5BEF46ADE30E

P478

Q33413239-CEEE614F-54B4-49B1-AFB8-4C93EBED0993

P577

Q33413239-967A566C-A2F5-4745-9593-15665E075A61

P698

Q33413239-FD126DEC-BF3C-4D14-9C4E-F5E0A74B2812

P921

Q33413239-D2634FC9-D6FD-4971-89E4-566E4B1B234D

P356

S11255-014-0663-8

P1433

International Urology and Nephrology

P1476

Sunitinib for refractory malignant pheochromocytoma: two case reports.

@en

P2093

Hidenori Akaihata

http://www.w3.org/2001/XMLSchema#string

Junya Hata

http://www.w3.org/2001/XMLSchema#string

Kei Ishibashi

http://www.w3.org/2001/XMLSchema#string

Masao Kataoka

http://www.w3.org/2001/XMLSchema#string

Nobuhiro Haga

http://www.w3.org/2001/XMLSchema#string

Norio Takahashi

http://www.w3.org/2001/XMLSchema#string

Souichiro Ogawa

http://www.w3.org/2001/XMLSchema#string

Tomoyuki Koguchi

http://www.w3.org/2001/XMLSchema#string

Yoshiyuki Kojima

http://www.w3.org/2001/XMLSchema#string

Yuichi Satoh

http://www.w3.org/2001/XMLSchema#string

P2860

Phase 2 study of everolimus monotherapy in patients with nonfunctioning neuroendocrine tumors or pheochromocytomas/paragangliomas.

Updated and new perspectives on diagnosis, prognosis, and therapy of malignant pheochromocytoma/paraganglioma.

Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas.

The diagnosis and management of malignant phaeochromocytoma and paraganglioma.

The evolving field of tyrosine kinase inhibitors in the treatment of endocrine tumors.

Sunitinib, a novel therapy for anthracycline- and cisplatin-refractory malignant pheochromocytoma.

Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients.

P304

1309-1312

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11255-014-0663-8

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

46

http://www.w3.org/2001/XMLSchema#string

P577

2014-02-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24510251

http://www.w3.org/2001/XMLSchema#string

P921

phaeochromocytoma